Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
Price : $35 *
At a glance
- Drugs SUN 0597 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 01 Sep 2016 Primary endpoint (Change in Total Nasal Symptom Score From Baseline to Day 14) has been met, according to the results published in the Annals of Allergy, Asthma and Immunology .
- 01 Sep 2016 Results published in the Annals of Allergy, Asthma and Immunology (2016).
- 08 Apr 2016 Treatment arms changed from 5 to 4 with removal of active comparator as reported by ClinicalTrials.gov.